---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-020042"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-07-17T23:59:59+00:00"
generated_at: "2026-05-18T06:01:56.771196+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Telomir-1 reverses STAT1 epigenetic silencing in prostate cancer, outperforming Paclitaxel and Rapamycin

## Summary
- In PC3 xenograft model, Telomir-1 fully reversed STAT1 hypermethylation after 21-day oral daily dosing.
- No STAT1 reversal was seen with Paclitaxel; only partial demethylation was observed with Rapamycin.
- Telomir-1 also reduced TMS1 hypermethylation, a pro-apoptotic tumor suppressor involved in immune signaling.
- Telomere length in tumor tissue was not elongated, addressing a key safety concern for telomere-targeting compounds.
- Company is advancing Telomir-1 toward IND filing and evaluating it in Wilson's disease, AMD, autism, and dysphonia.

## SEC filing metadata
- accession: 0001641172-25-020042
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000164117225020042/0001641172-25-020042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000164117225020042/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-020042
- JSON: https://secwatch.observer/filing/0001641172-25-020042.json
- Plain text: https://secwatch.observer/filing/0001641172-25-020042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.